

Assessment of Drug Resistance Patterns of Organisms Isolated From Urinary Tract Infections At Agartala Government Medical College, Agartala State Tripura, India

Arundhati Jamatia¹, Debasis Barman², Debashis Roy³,
Tarun Kumar Roy⁴, Debesh Debbbarma⁵, Rakesh Das⁶

¹Assistant Professor, Microbiology, Agartala Government Medical College

Abstract

Objective: This study was conducted to assess the pattern of uro- pathogens causing urinary tract infections (UTIs) and to determine their pattern of antimicrobial resistance.

Methods: It was an institution based cross-sectional study and conducted on 2630 urine samples. The clinical samples were cultured and bacterial strains were identified by Routine biochemical tests for primary identification of uro-pathogens in the department of microbiology. The antibiotic susceptibility profile of different bacterial isolates was studied according to Clinical and Laboratory Standards Institute (CLSI) guidelines to detect MDR, XDR and PDR bacteria. Statistical package for the social sciences (SPSS) 16 and Microsoft excel were used to analyse data.

Results: 421 samples were culture growth positive out of 2630 samples received from different department accounting 16% of growth positive. *Escherichia coli* was the predominant organism isolated from urine (37.07%) followed by *enterococcus* spp 24.94% *klebsiella* spp 21.61%. More XDR than MDR and 60.95% of the *Enterococcus* isolates were XDR followed by *Esch coli* and *Klebsiella* spp respectively. 26.19% isolates of *staphylococcus* were found to be MRSA strain and all are Vancomycin and Linezolid sensitive. *Pseudomonas* spp isolated very few but maximum isolates were XDR and ESBL producers.

Conclusion; *Escherichia coli*, *Enterococcus* and *Klebsiella* were the predominant pathogens causing urinary tract infection and have different resistant pattern. *Pseudomonas*, although isolated infrequently, demonstrates high resistance and ESBL producers. These findings underscore the importance of emphasizing infection control measures and judicious antibiotics use to prevent the development of resistance strains in bacterial isolates.

Keywords : Antimicrobial resistance, *Pseudomonas aeruginosa*, Methicillin Resistant *Staphylococcus aureus* (MRSA), *Enterococci* especially Vancomycin Resistant *Enterococci* (VRE), multidrug-resistant (MDR), extensively drug-resistant (XDR), and pandrug-resistant (PDR)

Introduction

Urinary tract infection and antimicrobial resistance is one of the major problem, with significant health and socioeconomic burden, particularly in developing countries¹. Due to recent dramatic change in

antimicrobial activity spectrum, we are trying to evaluate the current spectrum of antimicrobials activity in UTIs in our institution.

The bacterial causes of UTI include *Escherichia coli* (*E. coli*) (which causes 80% of the UTI), *Klebsiella pneumoniae* (*K. pneumoniae*), *Citrobacter* species, *Enterobacter* species, *Pseudomonas aeruginosa* (*P. aeruginosa*), and *Staphylococcus* species²⁻³. The mechanism of pathogenesis of the urinary tract infection by pathogens include adhesion to the host cell epithelium, invasion, immune evasion via cell wall lipopolysaccharide, capsule, and fimbriae⁴. As the infection is higher in females due to biological factors such as the short urethra, ano-genital proximity, and use of spermicides⁵. Urinary tract infection is mostly associated with increased resistance to antimicrobial agents like multidrug resistance (MDR) with substantial medical and a financial burden⁶⁻⁷.

Antimicrobial resistance is a major medical problem where microorganisms used varied resistance mechanisms such as horizontal gene transfer (such as plasmids and bacteriophages), genetic recombination, and mutations⁸. In addition, self-medication⁹, empirical therapy, misuse, and overuse of antimicrobials which are highly practiced everywhere hasten antimicrobial resistance (AMR) end up in prolonged illness, disability, increased health care costs, and death^{1,10,11}. In the era of rising antimicrobial resistance, current longitudinal studies revealing the prevalence and AMR trend of uropathogens are crucial to come up with this problem¹². In 2011, WHO declared “combat drug resistance: no action today, no cure tomorrow”¹³.

The clinical isolates such as *Pseudomonas aeruginosa*, Methicillin Resistant *Staphylococcus aureus* (MRSA), Enterococci especially Vancomycin Resistant Enterococci (VRE), and members of Family Enterobacteriaceae, for example, *Klebsiella pneumoniae*, *E. coli*, and *Proteus* sp rapidly develop antibiotic resistance and spread in the hospital environment. Actually, the health care planners have declared “Health for All by the year 2000.”¹⁴⁻¹⁵ In the last two decades, it was observed that there were so much increase of infectious diseases that the standard of public health in many parts of the world is equivalent to preantibiotic era¹⁶. As per standardized international terminology created by European Centre for Disease Control (ECDC) and Centre for Disease Control & Prevention (CDC), Atlanta, the multidrug-resistant (MDR), extensively drug-resistant (XDR), and pandrug-resistant (PDR) bacteria have been well defined¹⁷. Multidrug resistant (MDR) was defined as acquired non susceptibility to at least one agent in three or more antimicrobial categories. Extensively drug resistant (XDR) was defined as nonsusceptibility to at least one agent in all but two or fewer antimicrobial categories (i.e., bacterial isolates remain susceptible to only one or two antimicrobial categories). Pandrug resistant (PDR) was defined as nonsusceptibility to all agents in all antimicrobial categories.

The present study was undertaken to assess and up-to-date evidence of prevalence of isolates and their pattern of antimicrobial resistance which will support clinicians to identify the etiology of UTI, ensure appropriate empirical treatment for a reasonable period and an affordable cost. Moreover, it will help to health policymakers in implementing locally efficient therapy and preventive guidelines or advise effective measures to control the occurrence of multidrug-resistant infections in future.

Material and Methods

This short term institutional based cross-sectional study was conducted in the department of microbiology at Agartala govt medical College and GBP Hospital from 1st January 2023 to 30th June of 2023. The bacterial strains were isolated from urine samples of the suspected case of UTI from all the departments and were identified by conventional methods¹⁸. The clinical specimens received from both

indoor patient departments (IPD) and out door patients were included in the study. After the reception of the samples, we inoculated the samples on Cystine Lactose Electrolyte-Deficient agar and incubated for 24 h. After incubation, the culture plates were inspected for bacterial growth and results were recorded.

Case definition

Significant bacteriuria: Significant bacteriuria is defined as the presence of a significant quantity of bacteria in the urine, typically indicating UTI. The presence of a specific threshold of bacteria is considered significant (generally $> 10^5$ CFU/ml for a single bacterium). However, the threshold was considered lower than 10^5 for certain populations such as elderly age groups, males, symptomatic individuals, urinary catheters, low immune status, and urine collected via bladder aspiration¹⁹.

Antibiotic susceptibility test of bacterial strains was done by Kirby Bauer disc diffusion method²⁰ as per Clinical Laboratory Standard Institute (CLSI) guidelines²¹.

Antibiotics used for Gram positive cocci (GPC) were Amoxi-clavulanic acid, Ciprofloxacin, Doxycycline, Gentamycin, Vancomycin, Cefotaxime and linezolid and for Gram negative bacilli (GNB) were Amikacin, Cefotaxime, Amoxi-clavulanic acid, Ciprofloxacin, Meropenem, Tazobactam-piperacillin, Nitrofurantoin, Levofloxacin and Colistin and polymyxin B for *Pseudomonas* spp as they are reserved drugs, respectively. Linezolid and Colistin were used as supplemental drugs. For routine Quality Control of antibiotic susceptibility test, *S. aureus* ATCC 25923, *E. coli* ATCC 25922, and *Pseudomonas aeruginosa* ATCC 27853 were used.

MDR, XDR, and PDR strains were detected as per criteria described by ECDC and CDC²¹.

Methicillin Resistant *Staphylococcus aureus* (MRSA) strains were detected by *mecA*-mediated oxacillin resistance using cefoxitin disk (30 µg) on Mueller Hinton (MH) agar plate inoculated with test strains as per standard disk diffusion recommendations and incubated at 33–35°C for 16–18 hours. Inhibition zone ≤ 21 mm with cefoxitin disk was interpreted as *mecA* positive according to CLSI guidelines²² Cefoxitin is used as a surrogate marker for *mecA*-mediated oxacillin resistance. *S. aureus* ATCC 43300 was used as Quality Control for *mecA* positive strains.

Extended Spectrum β -lactamases (ESBL) producing strains were detected by combined disk method using ceftazidime (30 µg) and ceftazidime plus clavulanic acid (30 µg plus 10 µg)²³. An increase in diameter of ≥ 5 mm with ceftazidime plus clavulanic acid as compared to ceftazidime disk alone was considered positive for ESBL detection.

Inclusion and exclusion criteria: We have included the records of patients' data which contains the patients' age, sex, department of collection including indoor and out door patients department, type of sample quality (collected aseptically) and those samples lacking of at least one of the variables mentioned above were excluded.

Ethical approval letter was obtained from ethical review committee (ERC).

Data analysis

We used SPSS and Microsoft Excel to analyze the data and generate figures.

Results and observations: In the present study, we have first arranged the results based on department, indoor, outdoor and gender of the patients whose samples were processed for culture from suspected UTI. All age groups were included in the study. A total of 2630 number of clinical samples were included in the study, out of which 1764 samples were from indoor patients and 866 samples from out

door patients from different specialities . Samples received from indoor (67.07%) were more than the samples received from the outpatient department (32.93%). In the indoor the maximum samples were from the gynecology department followed by medicine and surgery. There were predominantly female samples received in both cases .

In present study UTI cases were more in female as compared to male i.e. female 2015 (80.04%) and Male : 615(23.38%) isolates were more in female than in males. Moreover, cumulatively 72% were females.

We observed that 421 samples showed growth out of 2630 samples received for cultures accounting Overall 16% samples of growth positive.

Among 2015 submitted samples of females, 356 (17.67%) were infected in female and 615 out of male , 65 (10.67%) males were suffering from UTI. Thus, explains comparatively greater risk of UTI in females.

Similarly, 1764 IPD samples , out of which 289 (68.65%) were positive and 866 OPD samples , 132 (32.12%) were suffering from UTI, thus showing higher rate of infection in indoor patients.

In present study E coli was the predominant organism isolated from urine accounting 37.07% of total isolates followed by Enterococcus spp 24.94% , klebsiella spp 21.61% , Staph aureus , Citrobacter spp , Pseudomonas spp 1.

Enterococcus was the leading predominant isolate in IPD accounting 30.80% followed by E coli , klebsiella spp , staphylococcus aureus , citrobacter and at last Pseudomonas spp. In present study the isolate of Pseudomonas was very less but showed highly resistance to multiple drugs.

In OPD, E coli (51.52%) was the predominant isolate followed by Klebsiella spp , Enterococcus, Staph aureus and Citrobacter spp.

E coli was more isolated in gynes/obs followed by medicine and pediatric department .

Enterococcus sp which was second most important isolates recovered mostly in obs and gyane department followed by klebsiella spp , Staph aureus and citrobacter spp.

Beside obs and Gyane department , Enterococcus spp was predominant isolate in Pediatric , ICU , casualty , orthopedic , surgery and chest department respectively .

Isolates were more XDR than MDR and among them 60.95% of the Enterococcus isolates were XDR followed by Esch coli and Klebsiella spp respectively . 26.19% isolates of staphylococcus were found to be MRSA strain and all the isolates are Vancomycin and linezolid sensitive. 50.49% of Enterococcus were high level Gentamycin resistance . Among MDR isolates Esch coli were more predominant isolates.

Pseudomonas spp isolated very few but maximum isolates were XDR and ESBL producers .

Antibiogram of Escherichia coli :156

Name of Antibiotics	Sensitive	Resistant
MRP	149 (95.51 %)	7 (4.49 %)
CXM	75 (48.08 %)	81 (51.92 %)
NIT	133 (85.26 %)	23 (14.74 %)
AMC	81 (51.92 %)	75 (48.78 %)
PIT	127 (81.41 %)	29 (18.59 %)
AK	137 (87.82 %)	19 (12.18 %)
LE	98 (82.82 %)	58 (17.18 %)

Esch coli showed highly resistance to CXM 51.91% followed by AMC (48.78%) and LE (37.18%).

Antibiogram of klebsiella spp.: 91

Name of Antibiotics	Sensitive	Resistant
MRP	85 (93.41 %)	6 (6.59 %)
CXM	51 (56.04 %)	40 (43.96 %)
NIT	51 (56.04 %)	40 (43.96 %)
AMC	53 (56.24 %)	38 (41.56 %)
PIT	78 (85 .71 %)	13 (14.29%)
AK	73 (80.22 %)	18 (19.78%)
LE	67 (73.63 %)	24 (26.37 %)

Klebsiella spp were highly resistance to CXM and NIT which is 43.96% both followed by AMC 41.56 % and LE 26.37% respectively .

Antibiogram of Citrobacter spp :16

Name of Antibiotics	Sensitive	Resistant
MRP	15 (93.75%)	1 (6.25%)
CXM	10 ((62.5%)	6 (37.5%)
NIT	12(75%)	4((25%)
AMC	10 (62.5%)	6 (37.5 %)
PIT	12 (75%)	4 (25 %)
AK	14 (87.5%)	2 (12. 5%)
LE	10 (87.5%)	6 (37.5 %)

Citrobacter spp were highly resistance to 37.5% to CXM and AMC and highly sensitive to MRP , AK and LE .

Antibiogram of Pseudomonas spp :8

Name of the Antibiotics	Sensitive	Resistant
MRP	3 (37.5%)	5 (62.5%)
CXM	3 (37.5%)	5 (62.5%)
NIT	0	8 (100%)
AMC	2 (25%)	6 (75%)
PIT	6 (75%)	2 (25%)
AK	2 (25%)	6 (75%)
LE	5 (62.5%)	3 (37%)

Pseudomonas were highly resistance to MRP and CXM (62.5%) both and 100% resistance to NIT . Out of 8 ,5 isolates were ESBL producers. And maximum are XDR .

Antibiogram of Enterococcus spp:105

Name of antibiotics	SENSITIVE	RESISTANT
AMC	51 (48.57%)	54 (54.43%)
CIP	32 (30.48%)	73 (69.52%)

DOX	29 (27.62%)	76 (72.38%)
CXM	21 (20%)	84 (80%)
VAN	105 (100%)	00
NIT	87 (82.86%)	18 (17.14%)
HGEN	52 (49.52%)	53 (50.48%)

Enterococcus spp were highly resistance to CXM (80%) followed by DOX (72.38%) , CIP (69.52%) and AMC (54.43%). All the isolates were sensitive to VAN 100%.

Antibiogram of Staphylococcus aureus : 42

Name of antibiotics	Sensitive	Resistant
AMC	27 (64.29%)	15 (35.71%)
CIP	27 (64.29%)	15 (35.71%)
DOX	29 (69.05%)	13 (30.95%)
CXM	30 (71.43%)	12 (28.57%)
VAN	42 (100%)	00
NIT	39 (92.86%)	3 (7.14%)
HGEN	39 (92.86%)	3 (7.14%)

Staph aureus showed higher resistance to AMC and CIP . all the isolates were 100% to van and LZ.

	MDR	XDR	MRSA/PAN/HGN/ESBL
E coli 156	18 (11.54%)	28 (17.95%)	(17.95%)
Klebsiella spp 91	8 (8.79%)	13 (17.95)	13(17.95)
Pseudomonas 8	1 (12.50)	4 (50%)	4 (50%)
Citrobacter 16	3 (18.75%)	1 (6.25%)	1(6.25%)
Enterococcus 105	7 (6.67)	64 (60.95%)	53(50.48%)
Staphylococcus 42	3 (7.19%)	7 (16.67%)	11 (26.96%)
	40 (9.50%)	117 (27.29%)	

Frequency distribution of MDR , XDR , PAN DRUGS , MRSA AND ESBL

Discussion

This study is mainly giving the present scenario of prevalence of MDR organisms causing UTI as there is emerging threat of MDR among uropathogenic organisms which is a major public problem, prolongs the treatment ,imposes disabilities and also reduces the life expectancy.

MDR are common in urinary pathogens due to environmental factors, host behavioral factors which dramatically changes the antimicrobial susceptibility of organisms. Therefore in present study, we evaluated the current spectrum of activity among uropathogenic organisms which will strengthen the knowledge of AMR through surveillance. In present study we have seen that the positive growth rate was 16 % which is much lower as compared to various other studies as for examples previously reported in Uttar Pradesh 43.61% (Ruchi Mishra, Jayesh, Singh, & Jasuja, 2016), 40–50%, and 39.6% (Rodríguez-Baño, Navarro et al., 2008). But, it was higher than the infection rate of 13.9% (Mohammed,

Alnour, Shakurfo, & Aburass, 2016). These findings advocated that the prevalence of UTIs varies greatly in different areas with time periods.

Our study reported that the infection rate was predominantly higher in admitted patients than outdoor and similar study was reported by Patel Soni, Bhagyalaxmi & Patel et al in their study on 2019 were stated 30.23% from OPD and 51.26% from IPD. On the other hand, 16% IPD and 17% OPD was reported in which was lower than our present study.

In our study, from indoor patient department predominant isolates were enterococcus which was 30.80% of total isolates followed by Esch coli, Klebsiella spp, Staph aureus, Citrobacter, Acinetobacter and Pseudomonas. (shown in table).

Common non-fermenters isolated were *P. aeruginosa* and *A. baumannii*, which were mostly involved in hospital-acquired infection rather than community-acquired. Though isolated very less numbers but *P. aeruginosa* had a greater prevalence than *A. baumannii* among the non-fermenters and they all were highly multi drugs resistant. Prevalence of *P. aeruginosa* exceeding *A. baumannii* has been documented in several studies.

Present study also shown a higher infection rate of (84.56%) in female than males of (15.44%). The number of females infected with UTI is 5.48 times more as compared with males which was much higher than the studies done by Mohammed et al. who reported 1.5 times higher risk of infection than males, 3.75 times in Muhammad Imran Khan et al which is bit similar but still lower than our study and others reported that females had 1.21 times more infection than males (Ruchi Mishra et al., 2016). Their findings are not similar to our findings. A study stated that there were predominantly females with a ratio of 13:7 (Pérez Heras, Sanchez-Gomez, Beneyto-Martin, Ruano-de-Pablo, & Losada-Pinedo, 2017) which was much higher than our present study. Although the rates of prevalence are different in several other studies.

In present study, out of 421 of total isolates where 37.05% was Esch coli followed by 24.94% of Enterococcus spp, Klebsiella spp 21.61% and 9.98% of Staph aureus respectively. Similar sequence of results of isolates were observed in several studies like by Muzammi et al where E coli was 39.6%, Enterococcus 33.9%, Pseudomonas spp 13.2%, MRSA 5.7% and in Sohail et al study 65% was E coli, Enterococcus spp 15%, Pseudomonas 6% and Staphylococcus aureus 1% which was not similar to the present study.

In our study enterococcus spp was the second most predominant isolate from urine and Klebsiella spp was the third followed by Staph aureus. There were few isolates of citrobacter spp, Pseudomonas spp, Acinetobacter and Candida spp and Serratia spp in our study.

But in study by Muhammad Imran Khan et al showed that Klebsiella spp was second most common isolate followed by Pseudomonas spp and in another study by Orrett, 2001 showed Proteus spp as second most common isolate. Our results are in agreement with the results reported in study (Muzammil, 2020), where Enterococcus spp was the second most common followed by klebsiella spp, Staph aureus and Citrobacter spp. So these patterns of results in various studies are suggestive of prevalence in different countries, and places and even vary from institutions.

In present study susceptibility pattern of Esch coli shown much better than previous strains published before and compared to other studies. Esch coli showed sensitivity to meropenam, nitrofurantoin, levofloxacin and piperacillin-tazobactam, Amikacin were 95.51%, 85.26%, 82.82% and 81.41%, 87.82% and maximum resistant was observed with ceftriaxone and amoxi-clavulanic acid. A study in 2016 reported that E. coli was completely sensitive to Amikacin, Imipenem, and Meropenem (Mohammed et

al., 2016) which is bit similar to our results and indicates that *E. coli* has not been developed much resistance to these drugs.

Sensitivity rates of Amikacin 61.46%, Ceftazidime 25.89%, Ciprofloxacin 18.97%, Cotrimoxazole 32.02%, Imipenem 91.69%, Meropenem 91.89%, Nitrofurantoin 72.33%, Piperacillin+Tazobactam 51.77% in *E. coli* as per studied by (Patel et al., 2019). *E. coli* showed resistant to oral drugs like Amikacin 8.21%, Cotrimoxazole >67%, Ciprofloxacin >74%, Nitrofurantoin >5–6%, and 6.19% in Tazobactam+Piperacillin (Sood & Gupta, 2012).

A study reported the sensitiveness of *E. coli* for Amikacin was 65%, Ciprofloxacin 15.61%, Ceftriaxone 20.81%, Cefotaxime 21.1%, Ceftazidime 21.1%, Nitrofurantoin 63%, Imipenem 92.77%, and Piperacillin+Tazobactam 70.80% (Ruchi Mishra et al., 2016).

Another reported the susceptibility of *E. coli* was Augmentin was 80%, Amikacin 60%, Piperacillin+Tazobactam was 90.66%, Ciprofloxacin 54.66% Ceftazidime and Ceftriaxone 33.33%, Cefotaxime 28%, Imipenem 100%, and Nitrofurantoin was 66.66% (Kumar, Singh, Ali, & Chander, 2014). A study in Saudi Arabia reported that 96.7% showed complete resistance to >5 antibiotics and moreover 16 isolates even to 10 tested the antibiotics showing dramatic multidrug resistance (Yasir et al., 2018). The drugs they tested included Amikacin, Amikacin, Ceftazidime, Cefepime, Ciprofloxacin, Cefalotin, Cefoxitin, Ceftriaxone, Gentamycin, Imipenem, Meropenem, Tigecycline.

These studies shows that *E. coli* is evolving very quickly, sensitivity rates are decreasing and resistivity rates are booming very fast and the multidrug resistance may vary with the variation of geographical location and some other factors as several has reported previously.

Enterococci was the second most predominant isolates in present study as it is a notorious pathogen because of its intrinsic resistance/tolerance to different group of antibiotics and is a main causative agent of gram positive UTI. By observing the various parameters of present study it can be concluded that enterococci which was thought to be a commensal organism is now emerging as a potential pathogen, particularly among hospitalised patients. In our study enterococcus was 24.94 % of total isolates . enterococcus still were 100% sensitive to Vancomycin as well as linezolid too. (100%) Resistance mostly seen with cephalosporin groups of drugs which is similar with sohail et al study where all 18 (15.0%) cultures were resistant to cefotaxime, ceftriaxone, and cefuroxime and also decreasing sensitivity with fluoroquinolone and aminoglycoside group of drugs . like ceftriaxone 20%, doxycycline 27.62% sensitive . Sohail et al. observed that the Enterococcus species were detected in 18 (33.9%) of all the positive cultures and 18 (100.0%) were sensitive to vancomycin; 15 (83.3%) were sensitive to linezolid; 13 (72.2%) were sensitive to ampicillin, amoxicillin, co-amoxiclav, teicoplanin, and penicillin G; and five (27.8%) were sensitive to ciprofloxacin which was quite similar to our study .

Among MDR enterococci, three dangerous resistance mechanisms are spreading: VRE (Vancomycin-Resistant *Enterococcus*), GRE (Glycopeptide-Resistant *Enterococcus*), and even LRE (Linezolid-Resistant *Enterococcus*) . The use of glycopeptides and linezolid in empirical therapy may increase enterococcal resistance to these antibiotics and lead to the spread of super-resistant bacteria with no chance of treatment.

In present study have been observed 50.48% enterococcus isolates were Aminoglycoside resistant and was detected by Gentamicin 120 µg disc show considerably high resistance to Gentamicin the result is similar to study of Sanal C. Fernandes et al.

Natural intrinsic tolerance to Aminoglycosides has been shown by enterococci. This property is due to two main factors, poor entry of antibiotic and inactivation of antibiotic by covalent modification of the hydroxyl or amino groups by naturally occurring enterococcal enzymes. In addition to this enterococci can modify the ribosomal target by the action of ribosomal RNA (rRNA) methyltransferase known as EfmM.

In present study have shown highest resistance to Fluoroquinolone like ciprofloxacin 69.52%, and most effective are Aminoglycosides, Nitrofurantoin, Ampicillin, Vancomycin and Linezolid which was almost similar to Sohail et al study .

observed the prevalence of Enterococci to be more than that of *S. aureus*, results similar to those seen in the current study .

Third important isolate was *Klebsiella* spp showed better results from previous study and mostly were sensitive to drugs like meropenem 93.41%, tazobactam-piperacillin 85.71% , Amikacin 80.22% , and levofloxacin 73.63% , respectively . A study conducted by Mohammed et al., 2016 shown Amikacin 100%, Imipenem 100% meropenem 92.3%, Ceftazidime 75.4%, Ceftriaxone 71.5%, Augmentin 71.5%, Piperacillin+Tazobactam 76.9%, Nitrofurantoin 46.2% and Ciprofloxacin 69.2%. but our study resistance mostly seen in drugs like ceftriaxone 43.96% , nitrofurantoin 43.96% , amoxi-clavulanic acid 41.56% and levofloxacin in fluoroquinolone group 26.27%. as reported by Patel et al in their study on 2019 Sensitivity rates of Amikacin 44.66%, Ceftazidime 19.76%, Ciprofloxacin 22.13%, Cotrimoxazole 27.27%, Imipenem 75.89%, Meropenem 75.49% in *Klebsiella* . A study reported the sensitiveness of *K. pneumoniae* for Amikacin 62.84%, Ciprofloxacin 17.48%, Ceftriaxone 13.11%, Cefotaxime 12.56%, Ceftazidime 13.66%, Nitrofurantoin 61.20%, Imipenem 90.71%, and Piperacillin+Tazobactam 65.51% by Ruchi Mishra et al., 2016. Another reported that *K. pneumoniae* susceptibility rates were 89.5% for Augmentin, 94.7% for Amikacin, 87.3% for Cefotaxime, 89.3% for Ceftazidime, 85% for Ciprofloxacin, 97.5% for Imipenem, 99.3% for Meropenem, and 91.3% for Piperacillin+Tazobactam by Lin et al., conducted on 2016 . Further, the antimicrobial activities of Ciprofloxacin and Moxifloxacin against *K. pneumoniae* were 75% and 67.5%, respectively by Grillon, Schramm, Kleinberg, & Jehl, on 2016 . Thus , these shows sensitivities reported very different from our studies and represent a big change in the spectrum of activities of antibiotics against *K. pneumoniae*. That is again an alarming situation for treatment .

In present study *Pseudomonas aeruginosa* isolated very less but were highly drugs resistance . All isolates were completely resistant to Nitrofurantoin , 75% strains were resistant to Amikacin and Amoxi-clavulanic acid , 62.50% isolates were resistant to Meropenem and ceftriaxone , only tazobactam – piperacillin and Levofloxacin were effective drugs for treatment of *pseudomonas aeruginosa* associated UTI . Colistin and polymyxin B are the reserved drugs for *Pseudomonas* spp which are still 100% sensitive to *pseudomonas* isolates in our present study . While Mohammed et al., 2016 and Patel et al. previously reported sensitivities for Amikacin, Imipenem, Meropenem, Ceftazidime, Ceftriaxone, Augmentin, Piperacillin+Tazobactam, Nitrofurantoin, and Ciprofloxacin were 88.9%, 88.9%, 77.8%, 88.9%, 0.00%, 0.00%, 100%, 0.00%, and 100%, respectively which have shown much similarity with our study .

A study reported by Ruchi Mishra et al. on 2016 that the sensitiveness of *P. aeruginosa* for Amikacin was 46.15%, Ciprofloxacin was 23.07%, Ceftriaxone was 11.54%, Cefotaxime was 11.54%, Ceftazidime was 19.23%, Nitrofurantoin was 3.84%, Imipenem was 80.76%, and Piperacillin+Tazobactam was 73.07%.

In our study also *P. aeruginosa* expressed strong resistance against Cephalosporin group of drugs and Nitrofurantoin. Our findings are also different from previously reported some studies and agree with some previously published findings. these findings indicate that susceptibility patterns also differ in different setups.

We have isolated very few 3.80% of *Citrobacter* spp from total isolates which showed much significance about *Citrobacter* in causing UTI. Sensitivity patterns showed much better results than other organisms causing UTI. 93.75% of *Citrobacter* sensitive to Meropenem, 87.5% to Amikacin, 75% to Nitrofurantoin and Tazobactam-piperacillin, 62.5% to levofloxacin, Amoxi-clavulanic acid, ceftriaxone. maximum resistance seen with Beta-lactam groups of drugs and fluoroquinolones. Sami et al on 2017 studied shown that 100% sensitive to imipenem, 66.2% Nitrofurantoin, 82.2% to Amikacin and least sensitivity was observed in tazobactam-piperacillin 23.1%.

Of the *S. aureus* isolated, 24% were methicillin-resistant *S. aureus* (MRSA). Susceptibility to vancomycin, teicoplanin, and linezolid was 100%, while susceptibility to erythromycin, clindamycin, gentamicin, trimethoprim-sulfamethoxazole, fusidic acid, and tetracycline, was 86%, 93%, 97%, 91%, 68%, and 87%, respectively.

In present study 9.98% were *Staphylococcus aureus* isolated in urine which is slightly higher than the usual prevalence rate 2-4% in urine causing UTI. Antimicrobial susceptibility pattern of *Staphylococcus aureus* shown were, 100% sensitive to Vancomycin, and Linezolid. Sensitivity to others drugs were much better than the previous study as 92.86% sensitive to Nitrofurantoin and high level gentamicin, 64.29% were sensitive to Amoxi-Clavulanic acid and Ciprofloxacin, 71.43% to Ceftriaxone, 69.05% to Doxycycline. Mohammad K Alshomrani et al on 2023 studied showed that susceptibility to Vancomycin, Teicoplanin, and linezolid was 100%, while susceptibility to erythromycin, clindamycin, gentamicin, trimethoprim-sulfamethoxazole, fusidic acid, and tetracycline, was 86%, 93%, 97%, 91%, 68%, and 87%, and Of the *S. aureus* isolated, 24% were methicillin-resistant *S. aureus* (MRSA) respectively and in our study we have 26.96% were MRSA which was quite similar with our study.

High prevalence of XDR followed by MDR shown in our study and among them 60.95% of enterococcus were XDR which was quite unusual from others study followed by *Pseudomonas* spp which were isolated very few but 50% were XDR and 12.50% MDR. Isolates of *Escherichia coli* and *Klebsiella* were 17.95% XDR both /11.54% MDR/ 8.79% MDR and *Staphylococcus aureus* 16.67% XDR and 7.19% MDR.

In a study by Chowdhury et al on 2022 shown that MDR organism was identified in 23 patients (55%). *Escherichia coli* was the most common organism, found in 23 (59%) of the cultures, with the next being *Klebsiella* spp. 12 (30.8%), *Enterococcus* spp. 2 (5.1%), *Pseudomonas aeruginosa* 1 (2.6%), and *Staphylococcus aureus* 1 (2.6%). 28% exhibited of MDR pattern, 18% XDR and 1.9% PDR among *E. coli* by Wajid M et al.

The MDR Gram-negative isolates accounted for 105 (83.3%), and Gram-positive isolates 21 (16.7%). The predominant MDR bacterium was *E. coli* 60 (47.6%), followed by *K. pneumoniae* 24 (19.1%), *S. aureus* 13 (10.3%), *P. mirabilis* and *S. saprophyticus* 8 (6.4%), *Pseudomonas* spp. 6 (4.8%), *P. vulgaris* 4 (3.2%) and *K. rhinos* 3 (2.4%). Extensive (XDR) and pan-drug resistant (PDR) isolates were 63 (24.8%) and 6 (4.8%), respectively and *Escherichia coli* was the most common MDR and XDR bacteria, while *Pseudomonas* was the only PDR isolate by Getachew Bitew et al. In study by Silpi et al, among 202 *E. coli* isolates, 28% are MDR strains, 8% are XDR, and 1.9% are PDR. This is similar to the study conducted by Silpi et al.

Conclusion

In conclusion, our study highlights that the *Escherichia coli*, *Enterococcus* and *Klebsiella* are the predominant pathogens exhibiting distinct resistance patterns. Notably, *Pseudomonas*, although isolated infrequently, demonstrates high resistance and ESBL production. These findings underscore the importance of emphasizing infection control measures and judicious antibiotics use to prevent the development of resistant strains in bacterial isolates. Now, time has come to use alternative therapeutic strategies in combination with drugs. For example combining two therapies, i.e. Near-infrared red radiations could sensitize the microbes first (Ha & Kang, 2015) and then antibiotics could easily kill the microbes. Moreover, recently it has been reported that metal organic frameworks (nanomaterial used in several disciplines) have also increased the activity of vancomycin against *Staphylococcus aureus*. (Iqra Ghaffar et al., 2019) and use of Cefazolin loaded chitosan nanoparticles to cure multi drug resistant Gram-negative pathogens. Exposure of MDR pathogens to the chitosan nanoparticles led to the disruption of cell membranes and the leakage of cytoplasm.

This indicates that use of nanomaterials could have promising applications in therapeutics as well in future to combat MDR pathogens.

References

1. Ahmed SS, Shariq A, Alsallloom AA, Babikir IH, Alhomoud BN. Uropathogens and their antimicrobial resistance patterns: Relationship with urinary tract infections. *Int J Health Sci* (Qassim). 2019;13(2):48–55. pmid:30983946 [View Article](#) , [PubMed/NCBI](#) , [Google Scholar](#)
2. Bitew A, Molalign T, Chanie M. Species distribution and antibiotic susceptibility profile of bacterial uropathogens among patients complaining urinary tract infections. *BMC infectious diseases*. 2017;17(1):654. pmid:28962545 [View Article](#) [PubMed/NCBI](#) [Google Scholar](#)
3. Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. *Nature reviews microbiology*. 2015;13(5):269–84. pmid:25853778 [View Article](#) [PubMed/NCBI](#) [Google Scholar](#)
4. Nguyen H, Tanagho E, McAninch J. Smith's general urology. 2004
5. [View Article](#) [Google Scholar](#)
6. Schaeffer A, Rajan N, Cao Q, Anderson B, Pruden DL, Sensibar J, et al. Host pathogenesis in urinary tract infections. *International journal of antimicrobial agents*. 2001;17(4):245–51. pmid:11295403 [View Article](#)
7. Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens. *The American journal of medicine*. 2002;113(1):14–9. pmid:12113867 [View Article](#) [PubMed/NCBI](#) [Google Scholar](#)
8. Nguyen H, Tanagho E, McAninch J. Smith's general urology. 2004. [View Article](#) [Google Scholar](#)
9. Schaeffer A, Rajan N, Cao Q, Anderson B, Pruden DL, Sensibar J, et al. Host pathogenesis in urinary tract infections. *International journal of antimicrobial agents*. 2001;17(4):245–51. pmid:11295403 [View Article](#) [PubMed/NCBI](#) [Google Scholar](#)
10. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. *The American journal of medicine*. 2002;113(1):5–13. [View Article](#) [Google Scholar](#)
11. Organization WH. WHO report on surveillance of antibiotic consumption: 2016–2018 early implementation. 2018.

12. Khameneh ZR, Afshar AT. Antimicrobial susceptibility pattern of urinary tract pathogens. *Saudi Journal of Kidney Diseases and Transplantation*. 2009;20(2):251. pmid:19237813 [View Article](#) [PubMed/NCBI](#) [Google Scholar](#)
13. Alemu A, Dagne M, Alem M, Gizachew M. Uropathogenic bacterial isolates and their antimicrobial susceptibility patterns among HIV/AIDS patients attending Gondar University Specialized Hospital, Gondar, Northwest Ethiopia. *Journal of Microbiology Research and Reviews*. 2013;1(4):42–51. [View Article](#) [Google Scholar](#)
14. Goossens H, Ferech M, Vander Stichele R, Elseviers M, Group EP. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. *The Lancet*. 2005;365(9459):579–87. pmid:15708101 [View Article](#) [PubMed/NCBI](#) [Google Scholar](#)
15. O'Neill J. Review on antimicrobial resistance. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. 2014;2014(4). [View Article](#) [Google Scholar](#)
16. Ashkenazi S, Even-Tov S, Samra Z, Dinari G. Uropathogens of various childhood populations and their antibiotic susceptibility. *The Pediatric infectious disease journal*. 1991;10(10):742–6. pmid:1945576 [View Article](#)
17. Sharma A. Antimicrobial resistance: no action today, no cure tomorrow. *Indian Journal of Medical Microbiology*. 2011;29(2):91–92. doi: 10.4103/0255-0857.81774. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
18. Rosenberger L. H., Hranjec T., Politano A. D., et al. Effective cohorting and 'superisolation' in a single intensive care unit in response to an outbreak of diverse multi-drug-resistant organisms. *Surgical Infections*. 2011;12(5):345–350. doi: 10.1089/sur.2010.076. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
19. Morales E., Cots F., Sala M., et al. Hospital costs of nosocomial multi-drug resistant *Pseudomonas aeruginosa* acquisition. *BMC Health Services Research*. 2012;12(1, article 122) doi: 10.1186/1472-6963-12-122. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
20. Krieg NR, Staley JT, Brown DR, et al. *Bergey's manual of systematic bacteriology*. Dordrecht: Springer, 2010
21. Arias C. A., Murray B. E. Antibiotic-resistant bugs in the 21st century—a clinical super-challenge. *The New England Journal of Medicine*. 2009;360(5):439–443. doi: 10.1056/nejmp0804651. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
22. Magiorakos A.-P., Srinivasan A., Carey R. B., et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clinical Microbiology and Infection*. 2012;18(3):268–281. doi: 10.1111/j.1469-0691.2011.03570.x. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
23. Magiorakos A.-P., Srinivasan A., Carey R. B., et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clinical Microbiology and Infection*. 2012;18(3):268–281. doi: 10.1111/j.1469-0691.2011.03570.x. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
24. Washington C. W., Jr., Stephen D. A., William M. J., et al. *Koneman's Color Atlas and Textbook of Diagnostic Microbiology*. 6th. Philadelphia, Pa, USA: Lippincott Williams & Wilkins; 2006. [[Google Scholar](#)]

25. Bauer A. W., Kirby W. M., Sherris J. C., Turck M. Antibiotic susceptibility testing by a standardized single disk method. *American Journal of Clinical Pathology*. 1966;45(4):493–496. [[PubMed](#)] [[Google Scholar](#)]
26. Clinical and Laboratory Standards Institute. *CLSI Document*. M100-S22. Wayne, Pa, USA: Clinical and Laboratory Standards Institute; 2012. Performance standards for antimicrobial susceptibility testing: 22nd informational supplement. [[Google Scholar](#)]
27. Carter M. W., Oakton K. J., Warner M., Livermore D. M. Detection of extended-spectrum β -lactamases in klebsiella with the oxoid combination disk method. *Journal of Clinical Microbiology*. 2000;38(11):4228–4232. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
28. [Muhammad Muzammil](#),¹ [Muhammad Adnan](#),² [Sheikh Muhammad Sikandar](#), Study of Culture and Sensitivity Patterns of Urinary Tract Infections in Patients Presenting with Urinary Symptoms in a Tertiary Care Hospital 2020 Feb; 12(2): e7013. Published online 2020 Feb 16. doi: [10.7759/cureus.7013](https://doi.org/10.7759/cureus.7013)
29. Characteristics and antibiotic resistance of urinary tract pathogens isolated from Punjab, Pakistan. Sohail M, Khurshid M, Saleem HG, Javed H, Khan AA. *Jundishapur J Microbiol*. 2015;8:0. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
30. Urinary tract infections in general practice in a rural community in South Trinidad Saudi Medical Journal, 22 (2001), pp. 537-540 View in Scopus [Google Scholar](#)
31. Wajid M, Mallamgunta S, Pedapati V and Naaz S et al . A study on evaluation of Escherichia coli isolates in urinary tract infection and its antibiogram in view of Emerging drug resistance at a tertiary care hospital. *Topical J of Path and Micro*. Vol 7 No 06 (2021): Nov-Dec.
32. Gupta S, Kapur S, Padmavathi D et al . Comparative prevalence of antimicrobial resistance in community-acquired urinary tract infection cases from representative States of northern and southern India. *J Clin Diagn Res*. 2014 Sep;8(9):DC09-12. doi: [10.7860/JCDR/2014/9349.4889](https://doi.org/10.7860/JCDR/2014/9349.4889) [[Crossref](#)][[PubMed](#)][[Google Scholar](#)]
33. haffar I., Imran M., Perveen S., Kanwal T., Saifullah S., Bertino M.F., Shah M. Ret al. Synthesis of chitosan coated metal organic frameworks (MOFs) for increasing vancomycin bactericidal potentials against resistant S. aureus strain. *Materials Science and Engineering: C*, 105 (2019), p. 110111.
34. Ha J.-W., Kang D.-H et al Enhanced inactivation of food-borne pathogens in ready-to-eat sliced ham by near-infrared heating combined with UV-C irradiation and mechanism of the synergistic bactericidal action *Applied and Environmental Microbiology*, 81 (2015), pp. 2-8.
35. Baral S, Pokharel A, Subramanya SH, et al. Clinico-epidemiological profile of Acinetobacter and Pseudomonas infections, and their antibiotic-resistant pattern in a tertiary care center, Western Nepal. *Nepal J Epidemiol* 2019; 9: 804–811.
36. De Francesco MA, Ravizzola G, Peroni L, et al. Prevalence of multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa in an Italian hospital. *J Infect Public Health* 2013; 6: 179–185.
37. Sohail M , khurshid M , Saleem HG , Javel H , Khan AA : Characteristic s and antibiotic reistance of urinary tract pathogens isolated from Punjab , Pakisthan , Jundishapu J Microbiol , 2015 8;e1972 vol 8 ,issue 7

38. Harshad Singh Naruka*, Anita E Chand, Harinandan Meena . Prevalence of various enterococcus species and their antibiotic resistance pattern among urinary isolates in tertiary care center in South Eastern Rajasthan, IJMMTD. Volume : 5, Issue : 1, Year : 2019 p : 18-22
39. Patel, H., Soni, S., Bhagyalaxmi, A., & Patel, N. (2019). Causative agents of urinary tract infections and their antimicrobial susceptibility patterns at a referral center in Western India: An audit to help clinicians prevent antibiotic misuse. *Journal of Family Medicine and Primary Care*, 8, 154.
40. .Lin, W.-P., Wang, J.-T., Chang, S.-C., Chang, F.-Y., Fung, C.-P., Chuang, Y.-C., ... Lauderdale, T.-L. (2016). The antimicrobial susceptibility of klebsiella pneumoniae from community settings in Taiwan, a trend analysis. *ScientificReports*,
41. Mishra, R., Jayesh, A., Singh, K., & Jasuja, K. (2016). Bacteriological profile and sensitivity pattern of microor ganisms causing urinary tract infection at a tertiary care center in eastern Uttar Pradesh. *International Journal of Biomedical and Advance Research*, 7, 292–297.
42. 40. Grillon, A., Schramm, F., Kleinberg, M., & Jehl, F. (2016). Comparative activity of ciprofloxacin, levofloxacin and moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia assessed by minimum inhibitory concentrations and time-kill studies. *PloS One*, 11, e0156690.
43. Mohammed, M. A., Alnour, T. M. S., Shakurfo, O. M., & Aburass, M. M. (2016). Prevalence and antimicrobial resis tance pattern of bacterial strains isolated from patients with urinary tract infection in Messalata Central Hospital, Libya. *Asian Pacific Journal of Tropical Medicine*, 9, 771–776.
44. Harshkumar B Patel , Sumeeta T Soni , Aroor Bhagyalaxmi ³, Neev M Patel et al. Causative agents of urinary tract infections and their antimicrobial susceptibility patterns at a referral center in Western India: An audit to help clinicians prevent antibiotic misuse. *Family Med Prim Care*.. 2019 Jan;8(1):154–159.
45. Sami, Hiba; Sultan, Asfia; Rizvi, Meher; Khan, Fatima; Ahmad, Shariq; Shukla, Indu; Khan, Haris M *Citrobacter* as a uropathogen, its prevalence and antibiotics susceptibility pattern. *CHRISMED Journal of Health and Research* 4(1):p 23-26, Jan–Mar 2017.
46. Adebola Onanuga , Godwin Oghenekparobo Awhowho et al . Antimicrobial resistance of *Staphylococcus aureus* strains from patients with urinary tract infections in Yenagoa, Nigeria . *J Pharm Bioallied Sci*. 2012 Jul-Sep;4(3):226–230
47. Mohammad K Alshomrani ¹, Ahmad A Alharbi ², et al. Isolation of Staphylococcus aureus Urinary Tract Infections at a Community-Based Healthcare Center in Riyadh. *NIH*: 2023 Feb 18;15(2).
48. Bikash Kumar Sah ¹, Prasanna Dahal ^{1,✉}, Shyam Kumar Mallik ¹, A Deevan Paul ², et al .Uropathogens and their antimicrobial-resistant pattern among suspected urinary tract infections patients in eastern Nepal: A hospital inpatients-based study .*SAGE Open Med*. 2023 Dec 25
49. Chowdhury, Md Ziaur R.; Benzamin, Md¹; Khatoon, Mohsina²; Tamal, Tuhin Bet al .Multidrug-resistant Organisms in Urinary Tract Infections in Bangladeshi Children*Paediatric Nephrology Journal of Bangladesh* 7(1):p 13-18, Jan–Jun 2022.
50. Getachew Bitew, Mulat Dagnew, Mahliet Dereje, Abebe Birhanu, Yalewayker Gashaw, Aklilu Ambachew & Belay Tessema et al.. *Scientific Reports* volume 15, (2025) Article number: 14270.